Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

【作者(必填)】Antonia SJ[size=0.8461em]1, Villegas A[size=0.8461em]1, Daniel D[size=0.8461em]1, Vicente D[size=0.8461em]1, Murakami S[size=0.8461em]1, Hui R[size=0.8461em]1, Yokoi T[size=0.8461em]1, Chiappori A[size=0.8461em]1, Lee KH[size=0.8461em]1, de Wit M[size=0.8461em]1, Cho BC[size=0.8461em]1, Bourhaba M[size=0.8461em]1, Quantin X[size=0.8461em]1,Tokito T[size=0.8461em]1, Mekhail T[size=0.8461em]1, Planchard D[size=0.8461em]1, Kim YC[size=0.8461em]1, Karapetis CS[size=0.8461em]1, Hiret S[size=0.8461em]1, Ostoros G[size=0.8461em]1, Kubota K[size=0.8461em]1, Gray JE[size=0.8461em]1, Paz-Ares L[size=0.8461em]1, de Castro Carpeño J[size=0.8461em]1, Wadsworth C[size=0.8461em]1, Melillo G[size=0.8461em]1, Jiang H[size=0.8461em]1, Huang Y[size=0.8461em]1, Dennis PA[size=0.8461em]1, Özgüroğlu M[size=0.8461em]1; PACIFIC Investigators.

【文题(必填)】[size=1.4em]Durvalumab[size=1.4em] [size=1.4em]after[size=1.4em] [size=1.4em]Chemoradiotherapy[size=1.4em] [size=1.4em]in[size=1.4em] [size=1.4em]Stage[size=1.4em] [size=1.4em]III[size=1.4em] [size=1.4em]Non-Small-Cell[size=1.4em] [size=1.4em]Lung[size=1.4em] [size=1.4em]Cancer[size=1.4em].

【年份(必填)】2017

【全文链接或数据库名称(选填)】https://www.ncbi.nlm.nih.gov/pubmed/?term=28885881